RE:RE:Pelareorep in 3rd line HR+/HER2 negative breast cancerSeptember 18, 2024 - Post ESMO 2024 Dr. Alessandra Curioni-Fontecedro, professor of oncology at the University of Fribourg and director of oncology at the Hospital of Fribourg, Switzerland, made the following observation "At ESMO 2024 we are seeing many studies in many different cancers showing that immunotherapy can work for a long time."
Improved overall survival with immunotherapy was also reported in early-stage triple-negative breast cancer (TNBC) and in muscle-invasive bladder cancer. Triple-negative breast cancers are particularly difficult to treat because they do not have estrogen or progesterone receptors or raised HER2 levels, so fail to respond to commonly used breast cancer treatments.
ONCY is currently awaiting the results of the independent investor sponsored IRENE Phase 2 study in TNBC involving INCYTE's PD-1 checkpoint inhibitor + pelareorep.
If the ESMO 2024 post-conference buzz is accurate, the IRENE results should follow the favorable pattern of results with I/O therapies reported on during ESMO.